NCT06270082 - Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

September 8, 2025

Study Completion Date

September 8, 2025

Conditions

Solid Tumor, AdultColorectal CancerPancreatic CancerMalignant MelanomaRas (Kras or Nras) Gene MutationBRAF Gene MutationCRAF Gene MutationNon-Small Cell Lung CarcinomaThyroid CarcinomaGliomas, Malignant

Interventions

DRUG

IK-595

Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.

Trial Locations (15)

15232

University of Pittsburgh Medical Center- Hillman Cancer Center, Pittsburgh

19107

Thomas Jefferson University, Philadelphia

20016

Johns Hopkins University of Medicine Sidney Kimmel Comprehensive Care Center, Washington D.C.

22031

INOVA Schar Cancer Institute, Fairfax

33136

University of Miami, Miami

37203

Sarah Cannon Research Institute, Nashville

49546

START Midwest, Grand Rapids

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

78229

Next Oncology- San Antonio, San Antonio

78758

Next Oncology, Austin

80218

Sarah Cannon Research Institute at HealthOne, Denver

91010

City of Hope, Duarte

92868

University of California Irvine, Orange